# Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage

> **NCT01275794** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1849 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01275794
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 1849 (ACTUAL)
- **Last updated:** 2012-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275794, "Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01275794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*